Citadel Advisors
HRTX icon

Citadel Advisors’s Heron Therapeutics HRTX Stock Holding History

Citadel Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$607K Sell
759,269
-1,335,776
-64% -$1.55M ﹤0.01% 8817
2025
Q4 		$2.72M Sell
2,095,045
-613,412
-23% -$757K ﹤0.01% 5347
2025
Q3 		$3.41M Buy
2,708,457
+486,620
+22% +$772K ﹤0.01% 5066
2025
Q2 		$4.6M Buy
2,221,837
+1,720,347
+343% +$3.51M ﹤0.01% 4255
2025
Q1 		$1.1M Buy
+501,490
New +$973K ﹤0.01% 6746
2024
Q4 		– Sell
-1,591,547
Closed -$2.58M – 14878
2024
Q3 		$3.17M Buy
1,591,547
+1,050,280
+194% +$2.51M ﹤0.01% 4692
2024
Q2 		$1.89M Sell
541,267
-32,170
-6% -$98.8K ﹤0.01% 5420
2024
Q1 		$1.59M Buy
573,437
+191,658
+50% +$482K ﹤0.01% 5974
2023
Q4 		$649K Buy
381,779
+371,389
+3,574% +$409K ﹤0.01% 7544
2023
Q3 		$10.7K Sell
10,390
-425,601
-98% -$606K ﹤0.01% 13047
2023
Q2 		$506K Sell
435,991
-613,808
-58% -$1.09M ﹤0.01% 7918
2023
Q1 		$1.59M Sell
1,049,799
-444,054
-30% -$1.11M ﹤0.01% 5810
2022
Q4 		$3.73M Buy
1,493,853
+441,157
+42% +$1.42M ﹤0.01% 4376
2022
Q3 		$4.44M Buy
1,052,696
+956,712
+997% +$3.74M ﹤0.01% 4070
2022
Q2 		$268K Sell
95,984
-115,588
-55% -$464K ﹤0.01% 10060
2022
Q1 		$1.21M Sell
211,572
-1,481,347
-88% -$10.8M ﹤0.01% 7270
2021
Q4 		$15.5M Buy
1,692,919
+1,552,390
+1,105% +$15.8M ﹤0.01% 2370
2021
Q3 		$1.5M Buy
140,529
+78,273
+126% +$953K ﹤0.01% 7076
2021
Q2 		$966K Sell
62,256
-440,222
-88% -$7M ﹤0.01% 8458
2021
Q1 		$8.14M Sell
502,478
-158,502
-24% -$2.83M ﹤0.01% 3297
2020
Q4 		$14M Buy
660,980
+539,643
+445% +$9.38M ﹤0.01% 2212
2020
Q3 		$1.8M Sell
121,337
-286,337
-70% -$4.47M ﹤0.01% 4918
2020
Q2 		$6M Sell
407,674
-1,101,232
-73% -$18.1M ﹤0.01% 2838
2020
Q1 		$17.7M Sell
1,508,906
-329,744
-18% -$6.2M 0.01% 1330
2019
Q4 		$43.2M Buy
1,838,650
+196,650
+12% +$4.35M 0.02% 862
2019
Q3 		$30.4M Buy
1,642,000
+324,462
+25% +$5.97M 0.01% 1114
2019
Q2 		$24.5M Buy
1,317,538
+367,914
+39% +$7.35M 0.01% 1239
2019
Q1 		$23.2M Sell
949,624
-1,692,479
-64% -$44.3M 0.01% 1202
2018
Q4 		$68.5M Buy
2,642,103
+756,523
+40% +$20.8M 0.04% 473
2018
Q3 		$59.7M Buy
1,885,580
+625,420
+50% +$23.3M 0.03% 658
2018
Q2 		$49M Buy
1,260,160
+329,647
+35% +$10.5M 0.02% 719
2018
Q1 		$25.7M Sell
930,513
-659,351
-41% -$15M 0.01% 949
2017
Q4 		$28.8M Buy
1,589,864
+1,404,870
+759% +$22.9M 0.02% 939
2017
Q3 		$2.99M Sell
184,994
-1,122,782
-86% -$17.6M ﹤0.01% 2929
2017
Q2 		$18.1M Buy
1,307,776
+24,097
+2% +$349K 0.02% 1056
2017
Q1 		$19.3M Buy
1,283,679
+1,106,946
+626% +$15.3M 0.02% 980
2016
Q4 		$2.31M Buy
+176,733
New +$2.77M ﹤0.01% 2778
2016
Q3 		– Sell
-213,517
Closed -$3.96M – 7427
2016
Q2 		$3.85M Buy
213,517
+185,564
+664% +$3.62M ﹤0.01% 2059
2016
Q1 		$531K Sell
27,953
-301,032
-92% -$5.94M ﹤0.01% 4329
2015
Q4 		$8.78M Buy
+328,985
New +$8.8M 0.01% 1378
2015
Q3 		– Sell
-35,784
Closed -$1.19M – 9028
2015
Q2 		$1.11M Buy
35,784
+20,081
+128% +$378K ﹤0.01% 3814
2015
Q1 		$228K Buy
15,703
+2,649
+20% +$29.9K ﹤0.01% 6020
2014
Q4 		$131K Buy
+13,054
New +$107K ﹤0.01% 6404

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Citadel Advisors's HRTX Position: Q1 2026 in Review

Citadel Advisors reduced its Heron Therapeutics (HRTX) stake by 64% in Q1 2026, selling an estimated $1.55M and leaving 759,269 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #8817.

Citadel Advisors first reported a position in HRTX in Q4 2014 and has held it in 43 quarters since. The position peaked at $68.5M in Q4 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Citadel Advisors held 759,269 shares of Heron Therapeutics worth $607K as of Q1 2026.
  • Citadel Advisors sold 1,335,776 Heron Therapeutics shares in Q1 2026, an estimated $1.55M.
  • Heron Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8817 holding.
  • Citadel Advisors first reported a position in Heron Therapeutics in Q4 2014 and has held it in 43 quarters since.
  • Citadel Advisors's Heron Therapeutics position peaked at $68.5M in Q4 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.